Oncology Net Income From Continuing Ops from 2010 to 2026
| TOIIW Stock | USD 0.10 0.02 16.67% |
Net Loss | First Reported 2020-12-31 | Previous Quarter -17 M | Current Value -16.5 M | Quarterly Volatility 10.7 M |
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 9.1 M, as well as many indicators such as Price To Sales Ratio of 0.0644, Dividend Yield of 0.0105 or PTB Ratio of 9.87. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
Oncology | Net Income From Continuing Ops | Build AI portfolio with Oncology Stock |
The evolution of Net Income From Continuing Ops for The Oncology Institute provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Oncology Institute compares to historical norms and industry peers.
Latest Oncology Institute's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of The Oncology Institute over the last few years. It is Oncology Institute's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Oncology Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (14,532,555) | |
| Coefficient Of Variation | (197.56) | |
| Mean Deviation | 22,980,864 | |
| Median | 3,947,974 | |
| Standard Deviation | 28,710,519 | |
| Sample Variance | 824.3T | |
| Range | 79.3M | |
| R-Value | (0.79) | |
| Mean Square Error | 337.3T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (4,463,771) | |
| Total Sum of Squares | 13188.7T |
Oncology Net Income From Continuing Ops History
About Oncology Institute Financial Statements
Oncology Institute investors use historical fundamental indicators, such as Oncology Institute's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -58.2 M | -55.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.